Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Single Doses of CC100
NCT02050334Phase 1Completed
- Sponsor
- Chemigen
- Start
- Nov 2013
- Primary completion
- Jul 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing CC100 (3 single doses) with CC100 (2 single doses) & placebo (2 arms). Primary endpoint: Unsolicited Adverse Event Reports. Started Nov 2013; status: completed.
02
Drugs
caffeic acid phenethyl ester
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02050334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050334.